Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Bioventus Q2 2024 Adj. EPS $0.19 Beats $0.07 Estimate, Sales $151.217M Beat $137.595M Estimate

Author: Benzinga Newsdesk | August 06, 2024 07:32am
Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.07 by 171.43 percent. This is a 35.71 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $151.217 million which beat the analyst consensus estimate of $137.595 million by 9.90 percent. This is a 10.32 percent increase over sales of $137.069 million the same period last year.

Posted In: BVS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist